Active, not recruitingPhase 2NCT05677113

A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver

Studying Fibrolamellar hepatocellular carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sunnybrook Health Sciences Centre
Principal Investigator
Paul Karanicolas
Paul.Karanicolas@sunnybrook.ca
Intervention
QBECO(drug)
Enrollment
115 enrolled
Eligibility
18 years · All sexes
Timeline
20232031

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05677113 on ClinicalTrials.gov

Other trials for Fibrolamellar hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Fibrolamellar hepatocellular carcinoma

← Back to all trials